Background {#Sec1}
==========

Proteasomes are located in both the nucleus and cytoplasm of cells, and they play a major role in the ubiquitin-dependent and ubiquitin-independent non-lysosomal pathways of intracellular protein degradation \[[@CR1], [@CR2]\]. Proteasomes are also involved in the turnover of various regulatory proteins (e.g., rate-limiting enzymes \[[@CR3]\] and proteins for cell-cycle control \[[@CR4]\] or transcriptional regulation \[[@CR5]\]), antigen processing \[[@CR6]\], cell differentiation \[[@CR7]\], and apoptosis \[[@CR8]\]. The 26S proteasome is a multicatalytic enzyme with a highly ordered structure composed of at least 32 different subunits arranged in two subcomplexes: a 20S core and a 19S regulator particle \[[@CR9]\]. The 20S-proteasome is composed of four rings of 28 non-identical subunits (two rings are composed of seven alpha subunits, and the other two rings are composed of seven beta subunits). Three of the seven beta subunits have proteolytic sites; the β1, β2, and β5 subunits are associated with caspase-like, trypsin-like, and chymotrypsin-like activities, respectively \[[@CR10]\]. These β1, β2, and β5 subunits cleave peptide bonds at post-acidic, −basic, and -hydrophobic amino acid residues, respectively \[[@CR10]\]. However, subunits β1, β2, and β5 could be replaced with β1i, β2i, and β5i by interferon-gamma (IFN-γ), and this IFN-γ-inducible proteasome isotype is called the immunoproteasome \[[@CR11]\].

The serum proteasome levels of patients with malignant tumors are elevated because the proteasome is overexpressed in tumor cells. In patients with multiple myeloma, serum proteasome concentrations have been shown to be associated with disease severity and activity \[[@CR12]\]: the serum proteasome concentrations were significantly elevated in patients with multiple myeloma compared to controls, in multiple myeloma versus monoclonal gammopathies of undetermined significance (MGUS), and in active versus smoldering multiple myeloma \[[@CR12]\]. Similarly, elevated serum proteasome levels were also reported in autoimmune diseases characterized by B-cell abnormality \[[@CR13]\]. In the present study, to determine the diagnostic value of the serum proteasome concentration in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), we investigated patients with myeloperoxidase (MPO)-AAV at various stages of the disease.

Patients {#Sec2}
--------

### Patients and controls {#Sec3}

We analyzed the cases of 44 patients with MPO-ANCA-associated microscopic polyangiitis (MPA) and renal involvement. The diagnosis of MPA was based on the European Medicines Agency algorithm \[[@CR14]\], and patients with other types of systemic vasculitis (including eosinophlic granuromatosis with polyangiitis, granulomatosis with polyangiitis, and anti-glomerular basement disease) were excluded.

Of the 44 MPO-AAV patients, 30 provided serum samples before the initial treatment, and 30 provided samples during remission; 16 provided samples both before the initial treatment and during remission. The Birmingham Vasculitis Activity Score (BVAS) was used to evaluate patients' disease activity, and remission was defined as a BVAS of 0. As controls, 14 healthy volunteers and 26 patients with chronic kidney disease (CKD) were investigated. The causes of CKD were nephrosclerosis (*n* = 10), chronic glomerulonephritis (*n* = 11), diabetic nephrosclerosis (*n* = 3), and autosomal dominant polycystic kidney disease (*n* = 2).

### Sample collection and analysis {#Sec4}

The serum samples measured by a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Enzo Life Science, Plymouth Meeting, PA, U.S.) in duplicate. In brief, 96-well microtiter plates were coated with a mouse anti-20S-proteasome alpha-6 subunit monoclonal antibody and left overnight at 4 °C, followed by blocking with phosphate-buffered saline (PBS) containing bovine serum albumin for 2 h at room temperature (RT). A serum sample was then added to each well, and the plates were incubated for 1 h at RT. A rabbit anti-20S-proteasome polyclonal antibody was then added to each well, and the plates were incubated for 1 h at RT, followed by incubation with a horseradish-peroxidase-labeled goat anti-rabbit IgG antibody for 1 h at RT. The plates were finally incubated with chromogen (tetramethylbenzidine) and hydrogen peroxide for 30 min at RT and then added with 1 N hydrochloride acid solution.

Between these steps, the plates were washed five times with Tris-buffered saline. The plates were immediately read on a microplate reader (Sunrise Remote®, Tecan Japan, Kanagawa, Japan) set at 450 nm with 540 nm as a reference wavelength. The inter- and intra-assay variations were \< 10%.

### Statistical analyses {#Sec5}

All statistical analyses were performed using PASW Statistics software, ver. 18 (IBM Japan, Tokyo) for Windows. The data are expressed as means ± standard deviations or as numbers with percentages of the total. The chi-square test with Yates' continuity correction and Fisher's exact test were used for differences in categorical variables, and post-hoc comparisons (Bonferroni correction) were performed to detect differences among three groups. The Mann-Whitney U-test was used for two-group comparisons, and we conducted an analysis of variance (ANOVA) to assess differences among three or more groups; post-hoc comparisons were made using the Bonferroni/Dunn test. Correlations were determined using Spearman's univariate correlation test and a linear regression analysis. The multiple linear regression analysis included the covariates shown to be significantly associated with the serum 20S-proteasome level in the correlation analysis, and the data are expressed as standardized regression coefficients (*β*). We applied comparative receiver-operating-characteristic (ROC) curves and the area under the curve (AUC) to assess the disease activity accuracy of the the serum 20S-proteasome level and inflammatory variables. *P*-values were accepted as significant at \< 0.05, but in the comparisons of three or more groups, the critical *p*-value was divided by the number of comparisons being made.

Results {#Sec6}
=======

The subjects' characteristics {#Sec7}
-----------------------------

The characteristics, clinical symptoms and laboratory data among the subjects of the three groups (the active-vasculitis patients, the inactive-vasculitis patients, and the controls) are shown in Table [1](#Tab1){ref-type="table"}. At the testing, there was no patients treated with any immunosuppressant in both active and inactive vasculitis, but all inactive-vasculitis patients had treated with corticosteroids (doses of prednisolone, 5.00 ± 1.97 mg/day). Table 1Characteristics of subjectsMPO-ANCA associated vasculitisControls (*n* = 40)Active-vasculitis (*n* = 30)Inactive-vasculitis (*n* = 30)Age (years)71.4 ± 14.269.7 ± 13.269.3 ± 12.0Gender (male:female)17: 1317: 1321: 19Birmingham vasculitis activity score20.7 ± 5.2^\*,\ \*\*^0 ± 0Clinical symptoms Fever21 (70%)^\*^0 (0%) Weight loss10 (33%)^\*^0 (0%) Arthralgia22 (73%)^\*^0 (0%) Episcleritis or uvitis2 (7%)0 (0%) Sinusitis1 (3%)0 (0%) Hearing loss3 (10%)0 (0%) Alveolar hemorrhage5 (17%)0 (0%) Interstitial lung disease15 (50%)13 (43%) Arrhythmia3 (10%)0 (0%) Pericarditis2 (7%)0 (0%) Heart failure9 (30%)^\*^0 (0%) Rapidly progressive glomerulonephritis25 (83%)^\*^0 (0%) Peripheral nerve damage1 (3%)0 (0%)Laboratory data ANCA titer (U/mL)255.7 ± 178.8^\*,\ \*\*^14.2 ± 30.4 White blood cell (/mm^3^)9483 ± 3380^\*,\ \*\*^8923 ± 3234^\*\*^5763 ± 1482 Hemoglobin conc. (g/dL)9.1 ± 2.0^\*,\ \*\*^11.7 ± 1.812.1 ± 2.0 Platelet count (10^4^/mm^3^)27.2 ± 12.0^\*,\ \*\*^21.2 ± 5.420.2 ± 6.0 Serum albumin (g/dL)3.05 ± 0.60^\*,\ \*\*^3.74 ± 0.37^\*\*^4.10 ± 0.34 Serum creatinine (mg/dL)4.55 ± 3.33^\*,\ \*\*^3.26 ± 3.961.76 ± 1.48 Serum C-reactive protein (mg/dL)7.92 ± 6.87^\*,\ \*\*^0.18 ± 0.160.09 ± 0.12 Serum 20S-proteasome (mg/dL)3414.6 ± 2738.9^\*,\ \*\*^366.4 ± 128.4234.9 ± 90.1Doses of prednisolone (mg daily)0 ± 0^\*^5.00 ± 1.97^\*^*P* \< 0.0167 vs. Inactive-vasculitis; ^\*\*^*P* \< 0.0167 vs. Controls

Serum 20S-proteasome levels {#Sec8}
---------------------------

As illustrated in Fig. [1](#Fig1){ref-type="fig"}, the mean level of serum proteasome in the active-vasculitis patients (3414.6 ± 2738.9 ng/mL) was significantly higher than those in the inactive-vasculitis patients (366.4 ± 128.4 ng/mL; *p* \< 0.0001) and the controls (234.9 ± 90.1 ng/mL; *p* \< 0.0001). There were significant positive correlations between the serum 20S-proteasome levels and the BVAS results (*r* = 0.581, *p* \< 0.0001), the MPO-ANCA titers (*r* = 0.384, *p* \< 0.0001), the WBC counts (*r* = 0.284, *p* = 0.0042), the platelet counts (*r* = 0.369, *p* = 0.0002), and the serum CRP levels (*r* = 0.550, *p* \< 0.0001). There were significant negative correlations between the serum 20S-proteasome levels and both the hemoglobin concentrations (*r* = − 0.351, *p* = 0.0003) and the serum albumin levels (*r* = − 0.460, *p* \< 0.0001). In the multiple regression analysis, there was a significant positive correlation between the serum 20S-proteasome levels and only the BVAS results (*β* = 0.851, *p* = 0.0009, Table [2](#Tab2){ref-type="table"}). Fig. 1The serum levels of 20S-proteasome. *Closed circles* = means, *bars* = standard deviations. *Open circles:* the values for individual patientsTable 2Correlation between the serum 20S-proteasome level and clinical parametersUnivariate analysisMultivariate analysis*rP*-value*βP*-valueAge0.0470.6424----Birmingham Vasculitis Activity Score0.581\< 0.00010.8510.0009ANCA titer0.384\< 0.0001−0.3350.0523White blood cell0.2840.0042−0.1370.3068Hemoglobin conc.−0.3510.00030.1530.3479Platelet count0.3690.00020.2200.0938Serum albumin−0.460\< 0.0001−0.1370.8223Serum creatinine0.1530.1282----Serum C-reactive protein0.550\< 0.0001−0.0310.8756

In the active-vasculitis patients, there was no association between the serum 20S proteasome levels and clinical symptoms except for pulmonary involvement (Supplementary file [S1](#MOESM1){ref-type="media"}). The mean serum 20S proteasome level in the active-vasculitis patients with interstitial lung disease (*n* = 15; 4994.3 ± 3025.8 ng/mL) was significantly higher than those in the active-vasculitis patients without pulmonary involvement (*n* = 10; 2110.0 ± 1114.0 ng/mL; *p* = 0.0045) and those in active-vasculitis patients with alveolar hemorrhage (*n* = 5; 1284.5 ± 515.9 ng/mL; *p* = 0.0040). There was no association between the serum 20S proteasome levels and the percentages of crescent formation, renal histological classification (Berden's classification \[[@CR15]\]), or renal symptoms (patients with chance proteinuria/hematuria and patients with rapidly progressive glomerulonephritis).

The diagnostic potential for disease activity {#Sec9}
---------------------------------------------

The optimum cut-off levels for the disease activity of vasculitis were identified from the ROC curves for the WBC count (\> 7250/mm^3^), serum CRP level (\> 0.72 mg/dL), and serum 20S-proteasome level (\> 563.1 ng/mL) (Fig. [2](#Fig2){ref-type="fig"}). The area under the curve (AUC) for the serum 20S-proteasome level was 0.996, which is higher than those of the WBC count (0.738) and the serum CRP level (0.963). On the ROC curve, the serum 20S-proteasome had 96.6% sensitivity and 95.5% specificity for the disease activity. Although the specificity of the serum 20S-proteasome level was less than that of the serum CRP level (100%), the sensitivity of the serum 20S-proteasome level was superior to that of the serum CRP level (89.7%; Table [3](#Tab3){ref-type="table"}). Fig. 2The comparative ROC curves for three measurements of disease activity. *Solid line:* serum levels of 20S-proteasome. *Dash-dotted line:* WBC counts. *Dashed line:* serum CRP levels. *Dotted line:* reference lineTable 3Comparative ROC curves for 3 parameters of disease activityArea under the curve95% confidence interval*P*-valueOptimal cut-off levelsSensitivity (%)Specificity (%)White blood cell count0.7380.624--0.851\< 0.001725072.468.7Serum C-reactive protein0.9630.000--1.000\<  0.0010.7289.7100Serum 20S-proteasome0.9960.000--1.000\< 0.001563.196.695.5

Discussion {#Sec10}
==========

Previous studies have demonstrated that the serum-20S-proteasome levels are elevated in individuals with autoimmune diseases. In 314 patients with various autoimmune diseases including systemic lupus erythematosus (SLE), polymyositis, Sjögren's syndrome, antiphospholipid syndrome, rheumatoid arthritis (RA), systemic sclerosis, autoimmune hepatitis, and myasthenia gravis, the serum proteasome levels were higher than in the 85 controls \[[@CR13]\]. The levels were especially (and significantly) high in the patients with SLE, polymyositis, Sjögren's syndrome, RA, and autoimmune hepatitis \[[@CR13]\]. In patients with polymyositis, serum proteasome levels were correlated with serum creatinine kinase levels, and serum proteasome levels were associated with disease activity \[[@CR13]\]. In the present study, elevated serum 20S-proteasome levels were also demonstrated in patients with AAV. Although there was no relationship between the MPO-ANCA titers and the serum 20S-proteasome levels, these elevations were associated with disease activity (i.e., the BVAS). Therefore, the serum level of 20S-proteasome may be a useful marker for disease activity in AAV.

The mechanisms that underlie the elevated serum proteasome observed in patients with AAV are not yet known. Several serum biomarkers are filtrated at the glomerulus and reabsorbed and catabolized by proximal tubular cells, and the serum levels of such biomarkers in patients with renal insufficiency are elevated due to low urinary filtration. Because we found no relationship between serum 20S-proteasome levels and serum creatinine in AAV patients, we conclude that elevated serum proteasome is not associated with renal function.

In a previous investigation, the serum proteasome levels in patients with multiple myeloma were elevated due to overexpression in tumor cells, but the mechanisms underlying these elevations in autoimmune diseases were not clarified \[[@CR16]\]. On the other hand, the structure and function of serum proteasome in healthy donors and patients with autoimmune diseases (SLE and RA) were maintained in the same manner as the intracellular forms \[[@CR16]\]. However, β-rings of proteasomes in the serum of patients with autoimmune diseases were different from those in healthy donors, and those rings contained immunosubunits β2i and β5i \[[@CR16]\]. Considering that proteasomes from non-immunocompetent cells do not contain immunosubunits \[[@CR17]\], it was speculated that serum proteasome in patients with autoimmune diseases may have its fraction structure added by an immunocompetent cell origin that is different from that in normal individuals. Therefore, the elevated serum proteasome levels in AAV may also be associated with the activation of immunocompetent cells. Further investigations are needed to clarify the mechanism by which the proteasome is released into the circulation.

Bortezomib, a proteasome inhibitor, prevents the degradation of proteins marked by ubiquitination by inhibiting the 26S proteasome \[[@CR18]\]. The main effects of bortezomib are NF-κB inhibition, inhibition of cell proliferation by the stabilization of cyclin-dependent kinases, the induction of apoptosis by the activation of c-Jun-NH~2~ terminal kinase, the stabilization of proapoptotic proteins and transcription factors and tumor suppressors, and the induction of cell death by activation of the terminal unfolded protein response \[[@CR19]\]. Bortezomib has been approved for clinical use in patients with multiple myeloma, and bortezomib treatment has implications for antibody-mediated immune diseases as well \[[@CR20]\].

The efficacy of bortezomib was demonstrated in a mouse model of MPO-ANCA-associated glomerulonephritis \[[@CR21]\]. That is, in anti-MPO-associated glomerulonephritis induced by immunizing MPO-deficient mice with murine MPO followed by irradiation and the transplantation of wild-type bone marrow, proteinuria (albuminuria) and hematuria were significantly reduced compared to the controls by both standard steroid/cyclophosphamide treatment and bortezomib treatment \[[@CR22]\]. Moreover, the percentage of glomeruli with crescent or necrosis formation was reduced by both treatments. The clinical efficacy of bortezomib for AAV has not been determined, because only one case of an AAV patient treated with bortezomib was reported. In that case, complete remission could not be achieved by a combination treatment with corticosteroid, cyclophosphamide, and rituximab; therefore, bortezomib (1.3 mg/m^2^/week for 4 weeks) was added \[[@CR22]\]. After the addition of bortezomib the patient achieved complete remission, and the doses of corticosteroid could be withdrawn \[[@CR22]\]. Thus, the proteasome may be associated with the development of AAV, and inhibition of the proteasome may be effective for inducing the remission of AAV.

Our study has several limitations. The study population was small and limited to MPO-AAV patients with renal involvement, and thus further studies are needed to compare patients with PR3-AAV or non-renal vasculitis. In addition, this was a retrospective cross-sectional study; a larger prospective longitudinal study (including vasculitis patients with relapse) would provide more definitive results. Since the present study was performed at one facility, it is necessary to verify the accuracy of the ELISA test. Moreover, all inactive-vasculitis patients were treated with corticosteroids at the testing, so treatments themselves may affected to decreased levels in inactive vasculitis. Therefore, further studies are needed to compare AAV patients without treatments at the testing, or to investigate other diseases patients treated with/without corticosteroids. Finally, although we did demonstrate that serum 20S-proteasome levels were elevated in our patients with AAV, the cause of this elevation was not identified. In patients with multiple myeloma, elevation of serum 20S-proteasome may be associated with overexpression in tumor cells or abnormal cellular turnover \[[@CR12]\]. On the other hand, elevation of serum 20S-proteasome was observed in septic patients and the relation between elevated serum 20S-proteasome levels and increased lymphocyte apoptosis was demonstrated in critically ill patients \[[@CR23]\]. In patinets with RA and SLE, it was speculated that the expression of inflammatory cytokines may have influenced the elevation of the serum 20S-proteasome \[[@CR13]\]. Althoug elevated serum 20S-proteasome in active AAV may be reflected an acute phase response, there was no significant correlation between the serum 20S-proteasome levels and serum CRP levels in the multiple regression analysis. To clarify the mechanisms of the serum 20S-proteasome elevation in vasculitis patients, further in vitro and ex vivo investigations are needed.

Conclusion {#Sec11}
==========

The serum levels of 20S-proteasome in our patients with active MPO-AAV were significantly elevated compared to the levels in the patients with inactive MPO-AAV and the controls. Moreover, the serum levels of 20S-proteasome were related to the BVAS results. The serum level of 20S-proteasome may therefore be a useful marker for disease activity in AAV.
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**Additional file 1: Supplementary file S1.** The relationships between the serum 20S proteasome levels and the patients' clinical symptoms.
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